VIP protocol · PepGuide

Shoemaker CIRS

Weeks 1–12

~50–100 mcg/dose

50 mcg per nostril · Up to 4×/day

Per administration: ~50–100 mcg/dose. Intranasal. Start lower; titrate. Course 30–90 days, then taper toward zero.

Taper

Reduce frequency

Goal is to gradually reduce to zero as regulation is restored.

Phase	How often	Dose	Units	Notes
Weeks 1–12	Up to 4×/day	50 mcg per nostril	~50–100 mcg/dose	Per administration: ~50–100 mcg/dose. Intranasal. Start lower; titrate. Course 30–90 days, then taper toward zero.
Taper	Reduce frequency	–	–	Goal is to gradually reduce to zero as regulation is restored.

Prereqs (CIRS): VIP is the last step, only after passing a VCS test and treating MARCoNS (nasal staph) per the protocol. Using it out of sequence can backfire. Note: compounded VIP is not FDA-evaluated for safety or efficacy.

Cycle & timing

Cycle: Course 30–90 days, then taper toward zero.

Timing: Up to 4×/day.

Where: Intranasal spray (primary). Rarely SubQ/IV in research.

What to expect

Improved inflammatory markers, energy, and quality of life in CIRS when used correctly at the end of the protocol. Not a standalone fix.

How much to buy

For 60-day course @ ~100–200 mcg/day:

3

× 5mg vials

2

× 10mg vials

Men & women

Largely unisex (immune / anti-inflammatory), dose by protocol. A uterine relaxant / vasoactive, avoid in pregnancy. Limited self-use data.

Recommended mixes

Vial	Water	Strength
5 mg	2.5 mL	2 mg/mL
10 mg	5 mL	2 mg/mL

5 mg: BAC water / Saline. Transfer to a metered nasal spray (~0.1 mL = 200 mcg/spray)

10 mg: Nasal reservoir, volume is the spray bottle

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: refrigerate 36–46°F; nasal bottle short-dated. Protect from light.

Don't use if: Hypotension / low blood pressure (vasodilatory) · Active MARCoNS or incomplete CIRS prerequisites (per protocol) · Pulmonary hypertension · Pregnancy and lactation

Stop if you notice

Significant blood-pressure drop, dizziness, or fainting
Worsening symptoms (may indicate out-of-sequence use)
Chest tightness or breathing difficulty

Side effects

Transient cough, flushing, lightheadedness, blood-pressure drop (vasoactive), GI upset. A first-dose blood-pressure check is prudent.

Drug interactions

Antihypertensives / vasodilators / PDE5 inhibitors: additive hypotension. Nitrates: caution with combined vasodilation.

Labs

CIRS labs per Shoemaker (TGF-β1, C4a, MMP-9, VIP level). Blood pressure monitoring, especially first dose.

What these labs mean →

Warnings

Vasoactive, can drop blood pressure; check BP on first dose. Must follow CIRS sequence (VCS pass, MARCoNS treated) or it can worsen symptoms. Compounded, not FDA-evaluated. Transient cough/flushing common early.

Patient education

This is the final step of the CIRS protocol, sequence matters. Check blood pressure on the first dose (it’s vasoactive). Compounded and not FDA-evaluated, use with a knowledgeable clinician. Stop for dizziness, fainting, or breathing difficulty.

These apply on top of the universal safety rules.

Pairs well with

CIRS protocol sequence

used within it (after MARCoNS clearance)

BPC-157

gut; not a typical performance stack

BPC-157

Avoid with

Low blood pressure / hypotension

Active MARCoNS or unfinished CIRS prerequisites

Pulmonary hypertension

Pregnancy

Can VIP + BPC-157 share a syringe?

Give it its own pin. VIP gets its own injection.

What it does

Intranasal delivery; not FDA-evaluated.

VIP is a 28-amino-acid neuropeptide with broad anti-inflammatory, immune-regulating, and vasoactive effects. In the Shoemaker CIRS protocol it’s the final-stage agent used to restore regulatory neuropeptide function after upstream steps are complete.

References

researchdosing peptidedosages PubMed thepeptidereport

From the guide, page 105.